Arrowhead Research Corporation (ARWR)
Arrowhead Research Corporation Revenues: 0.0313M
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
Select a metric
Date range:
to
<Embed Chart>
Pro Save as Image
Pro Data Export
Copy the code below and paste
into the embed destination.
into the embed destination.
Attention
OK
ARWR Revenues Rankings
| Overall | 0th percentile | 4403 of 4425 |
| Sector | 2nd percentile | 460 of 470 in Healthcare |
| Industry | 3rd percentile | 127 of 132 in Biotechnology |
ARWR Revenues Range, Past 5 Years
| Minimum | -0.0598M | Sep 2008 |
| Maximum | 2.633M | Jun 2009 |
| Average | 0.4830M |
About Revenues
Income that a company gains from business activities, calculated before any expenses are subtracted. Includes all sales and other increases in owner's equity.
Learn More
You may also be interested in these ARWR related companies
ARWR News
Arrowhead Presents Data on DPC System and Hepatitis B Program at CLINAM 2012
May 09, 7:00AM Business Wire
May 09, 7:00AM Business Wire
Arrowhead Research's CEO Hosts Alvos Acquisition Conference Call (Transcript)
May 08, 12:06AM Seeking Alpha
May 08, 12:06AM Seeking Alpha
$ARWR strong this morning. Long term resistance around 7. http://stks.co/3BF6
about 55 days ago by Xatta_Trading
about 55 days ago by Xatta_Trading
Breakout candidate: $ARWR http://stks.co/2l0W Other RNAi companies: $ALNY $TKMR
about 79 days ago by Xatta_Trading
about 79 days ago by Xatta_Trading
Arrowhead Releases White Paper on Hepatitis B Virus and Potential RNAi Treatment
Mar 07, 7:05AM Benzinga
Mar 07, 7:05AM Benzinga
Arrowhead Research (ARWR), Axolabs Enter Strategic Oligonucleotide Optimization Alliance
Mar 05, 7:05AM Street Insider
Mar 05, 7:05AM Street Insider
Arrowhead Announces Patent Issuance Covering siRNA Inhibitors of HIF-2α (EPAS1)
Feb 29, 7:00AM Business Wire
Feb 29, 7:00AM Business Wire
$ARWR gearing up for a run through 5.50. Keeping an eye on volume.
about 89 days ago by Xatta_Trading
about 89 days ago by Xatta_Trading
$RXII $GALE $MRNA $ALNY $CYTR $ARWR RIP140 regulation of diabetes Patent8093223 Czech(RXi Pharmaceuticals) http://stks.co/1tyQ
about 136 days ago by biotech
about 136 days ago by biotech
$ARWR filed latest Proxy Statement with the SEC (Form DEF 14A) http://stks.co/1tQB
about 136 days ago by MarketBrief
about 136 days ago by MarketBrief
FDA Grants Arrowhead (ARWR) Clearance to Initiate AdipotideTM Phase I Clinical Trial
Jan 04, 7:33AM Street Insider
Jan 04, 7:33AM Street Insider
Arrowhead Announces FDA Clearance to Initiate Adipotide Phase I Clinical Trial
Jan 04, 7:30AM Benzinga
Jan 04, 7:30AM Benzinga
Arrowhead Announces FDA Clearance to Initiate AdipotideTM Phase I Clinical Trial
Jan 04, 7:30AM Business Wire
Jan 04, 7:30AM Business Wire
Arrowhead Reports Fiscal 2011 Fourth Quarter and Year-End Financial Results
Dec 20, 4:01PM Business Wire
Dec 20, 4:01PM Business Wire
Arrowhead Research (ARWR) Announces Plans for 1-for-10 Reverse Stock Split
Nov 16, 4:11PM Street Insider
Nov 16, 4:11PM Street Insider
Leonardo Biosystems Receives Second $1.25 Million Investment from the Texas Emerging Technology Fund
Nov 14, 7:00AM Business Wire
Nov 14, 7:00AM Business Wire
$ARWR Arrowhead Research Corporation Bid Price NCM Nasdaq Deficiency due 2011/6/6
about 355 days ago by canarionyc
about 355 days ago by canarionyc
$ARWR has touched support many times ... looks like it is breaking down here ...
about 490 days ago by Drew_Yoshida
about 490 days ago by Drew_Yoshida
Arrowhead * $ARWR * increases investment in RNAi subsidiary Calando & announces Unidym acquisition by Wisepower http://www.arrowres.com/
about 495 days ago by tpgir
about 495 days ago by tpgir
Recent Quotes
| Symbol | Price | Chg | Chg % | Market Cap |
|---|---|---|---|---|
| ARWR | 4.120 | -0.05 | -1.20% | 43.38M |
| ARW | 34.34 | +0.02 | +0.06% | 3.838B |
| ARUN | 13.70 | -0.18 | -1.30% | 1.504B |
| ARTX | 0.88 | -0.11 | -11.11% | 13.70M |
| ARTW | 7.15 | -0.15 | -2.05% | 28.81M |
| ARTNA | 19.24 | -0.16 | -0.82% | 165.85M |
| ARII | 21.36 | -0.65 | -2.95% | 456.04M |
| ARIA | 16.77 | -0.08 | -0.47% | 2.665B |
| ARI | 15.89 | -0.12 | -0.75% | 326.70M |
| ARGN | 12.21 | -0.32 | -2.55% | 352.26M |